Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients

Polymyxin B (PB) has reemerged as a common treatment against multidrug-resistant Gram-negative pathogens. However, nephrotoxicity remains a significant dose-limiting side effect, and contemporary pharmacokinetic (PK) data are limited. This study sought to evaluate PB exposure differences in various...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Antimicrob Agents Chemother
Autori principali: Miglis, Cristina, Rhodes, Nathaniel J., Avedissian, Sean N., Kubin, Christine J., Yin, Michael T., Nelson, Brian C., Pai, Manjunath P., Scheetz, Marc H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2018
Soggetti:
Pharmacology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5826159/
https://ncbi.nlm.nih.gov/pubmed/29311071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01475-17
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi